Guidance

Guidance on pharmacovigilance procedures in the event of a no-deal Brexit

This guidance summarises our approach to pharmacovigilance in the event of no-deal Brexit.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 18 March 2019
• Last updated: 9 October 2019
  Show all updates

  1. 9 October 2019

     Major changes to content, including two new sections (9 and 10).

  2. 9 October 2019

     Change of text within Stay up to date box.

  3. 18 March 2019

     First published.

This publication was withdrawn on 24 February 2020

For current information on pharmacovigilance procedures see European Medicines Agency: Post-authorisation

Documents

Updated guidance on pharmacovigilance procedures in the event the UK leaves the EU without a deal

HTML

Details

This guidance will apply from exit day in line with the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019.